The small print...
‘Black Hole Quencher', ‘BHQ-1', ‘BHQ-2', ‘Quasar', ‘Q-570' and ‘Q-670' are trademarks of Biosearch Technologies, Inc., Novato, CA. The Black Hole Quencher technology is protected in the United States and other countries by U.S. patents and continuations numbered 7,019,129, 7,019,129B1 and 7,019,312B2 issued to Biosearch Technologies, Inc. The Quasar technology is covered by U.S.P.T.O. patent application number US2005/0214833A1. Products incorporating the BHQ or Quasar dye moiety are sold exclusively for R&D use by the end user. They may not be used for clinical or diagnostic purposes and they may not be re-sold, distributed or re-packaged. For information on licensing programs to permit use in commercial applications, please contact licensing@biosearchtech.com.
The use of EDITH in the US is protected under US Patent No. 5,852,168 and licence for such use must be sought from The University of Minneapolis.
A licence may be required from Isis Pharmaceuticals, Inc. to incorporate 2'-fluoro modified nucleosides into oligonucleotides as claimed in US Patent Numbers 5,670,633, 6,005,087, 6,531,584 and foreign equivalents.
OPeCTM is a trademark of Link Technologies Ltd, Bellshill, Scotland.
The Photocleavable (PC) Modifiers were developed by Ambergen Inc., Massachusetts, US, Link Technologies Ltd, Bellshill, Scotland and Glen Research Corp., Virginia, US and are made available under licence from Ambergen Inc.
PNA monomers are manufactured and sold pursuant to license under one or more of US Patents Nos. 5,773,571, 6,133,444, 6,172,226, 6,395,474, 6,414,112, 6,613,873, 6,710,163 and 6,713,602, or corresponding patent claims outside the US. PNA Monomers are sold to be used for internal research use only, and are not to be resold unless by separate licence.
SolidCPRTM is sold by agreement with Glen Research, Corp., Virginia, US under EP Patent No. 0816368.
SynBaseTM is a trademark of Link Technologies Ltd, Bellshill, Scotland.
2'-TC Monomers:
Applicable to end user customers either directly or through distributors: This product is manufactured and sold under a license from Agilent Technologies under pending U.S. Patent App. Nos. 12/118,655, 61/099,131, PCT/US08/63342 and corresponding foreign counterparts. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patents to use the product to synthesize oligonucleotides for buyer's internal research use only, including commercial purposes. Except as otherwise provided herein, no other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. Buyer agrees and understands that it is not licensed to use this product to synthesize oligonucleotides for sale, for diagnostic uses including use in a clinical diagnostic setting where the use in conjunction with an individual's sample generates data provided to an individual or the individual's caregiver for a fee or reimbursement, neither can oligonucleotides synthesized using this product be used for use clinical trials or for other therapeutic purposes. This product is sold pursuant to authorization from Agilent Technologies, Inc. and Agilent Technologies reserves all other rights under these patents.
Applicable where the purchaser is required to have its own direct license from Agilent, without limitation (Bulk Quantity Sales, and sales to Oligo Houses): This product and its uses are covered by pending U.S. Patent App. Nos. 12/118,655, 61/099,131, PCT/US08/63342 and corresponding foreign counterparts assigned to Agilent Technologies. This product is sold to purchaser pursuant to authorization by Agilent Technologies, Inc. without any rights conferred by seller, based on purchaser's direct license and authorization to purchase from Agilent Technologies, Inc. No license is granted to the purchaser whether expressly, by implication, by estoppel or otherwise on account of this purchase. Purchaser's rights to use this product are governed solely and expressly by purchaser's direct license agreement with Agilent.
UNA
Use of UNA monomers is protected by pending U.S. Patent App. No. 61/090165 and PCT/US08/64417 owned by MDRNA Inc. and exclusively licensed with respect to reagents and diagnostic products and uses to Ribotask ApS. The UNA monomers are sold under a marketing agreement with Ribotask ApS. The UNA monomers may not be used to manufacture oligos for sale or for diagnostic or clinical uses. A licence to use the UNA monomers in commercial reagents or for diagnostic applications must be obtained directly from Ribotask ApS.
Website content © Link Technologies Ltd. Unless otherwise specified, no content from this website may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without the prior written permission of Link Technologies Ltd.